Response to Pegylated Interferon Plus Ribavirin in Patients with Hepatitis C Virus Genotype 6a Infection from Guangdong and Guangxi Province of China
Table 1
The baseline characteristics of patients with different HCV genotype infection.
Characteristics
HCV-6a ()
HCV-2/3 ()
HCV-1b ()
value
(24 w, )
(48 w, )
Age (years)
34.2 ± 11.6
36.6 ± 10.6
36.5 ± 14.06
36.7 ± 13.03
0.639
BMI
22.0 ± 4.0
22.1 ± 3.9
22.1 ± 2.62
22.4 ± 3.93
0.36
Male ()
40 (62.5%)
59 (63.3%)
62 (60.2%)
163 (62.9%)
0.857
IDU ()†
17 (26.6%)
25 (28.1%)
14 (13.6%)
24 (9.3%)
<0.001
Blood transfusion ()
15 (23.4%)
21 (23.6%)
37 (35.9%)
149 (57.5%)
<0.001
Family history of HCC ()†
4 (6.2%)
6 (6.7%)
4 (3.9%)
7 (2.7%)
0.302
PEG-IFNα-2a ()
50 (78.1%)
67 (75.3%)
85 (82.5%)
223 (86.1%)
0.094
ALT (U/L)
82.9 ± 8.1
80.0 ± 6.9
87.9 ± 3.0
78.1 ± 9.0
0.955
HCV RNA (IU/mL)
6.1 ± 1.0
6.2 ± 1.1
5.6 ± 1.1
6.4 ± 0.9
0.106
Cirrhosis ()
6 (9.4%)
5 (5.6%)
9 (8.7%)
37 (14.3%)
0.118
BMI, body mass index; †IDU, intravenous drug use; HCC, hepatocellular carcinoma; ALT, alanine aminotransferase; HCV RNA, hepatitis C virus ribonucleic acid; cirrhosis, the cut point of ≥14.5 kpa for ≥F4 stage fibrosis; value comparing the different genotype groups.
